Arvinas Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Arvinas Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3331
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of pro-inflammatory, cancer, autoimmune and rare diseases. Its proprietary approach is to target disease causing proteins. Arvinas’s protein degradation technology platforms include proteolysis-targeting chimera and hydrophobic tagging which induce the loss of intracellular proteins. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations. It also develops degraders for targets in cancer, including androgen receptor, estrogen receptor and BET proteins. Arnivas is headquartered in New Haven, Connecticut, the US.

Arvinas Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arvinas Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Arvinas Raises USD55 Million in Series C Financing 10
Arvinas Raises USD41.6 Million in Series B Venture Financing 12
Arvinas Raises US$18.25 Million In Series A Venture Financing 14
Arvinas Raises USD3.51 Million in Venture Financing 15
Partnerships 16
Arvinas Enters into Co-Development Agreement with Macroceutics 16
Licensing Agreements 17
Pfizer Enters into Licensing Agreement with Arvinas 17
Genentech Expands Licensing Agreement with Arvinas 18
Arvinas Enters into Licensing Agreement with Merck 19
Arvinas Enters into Licensing Agreement with Yale University 20
Arvinas Inc – Key Competitors 21
Arvinas Inc – Key Employees 22
Arvinas Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
Sep 20, 2017: Arvinas Appoints Dr. John Houston as President and Chief Executive Officer 24
Jan 05, 2017: Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer 25
Product News 26
12/20/2017: Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program 26
Clinical Trials 27
Dec 08, 2017: Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium 27
Nov 02, 2017: Arvinas Nominates Oral Clinical Candidate for Androgen Receptor Degrader Program 28
Feb 17, 2017: Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Arvinas Inc, Pharmaceuticals & Healthcare, Key Facts 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arvinas Raises USD55 Million in Series C Financing 10
Arvinas Raises USD41.6 Million in Series B Venture Financing 12
Arvinas Raises US$18.25 Million In Series A Venture Financing 14
Arvinas Raises USD3.51 Million in Venture Financing 15
Arvinas Enters into Co-Development Agreement with Macroceutics 16
Pfizer Enters into Licensing Agreement with Arvinas 17
Genentech Expands Licensing Agreement with Arvinas 18
Arvinas Enters into Licensing Agreement with Merck 19
Arvinas Enters into Licensing Agreement with Yale University 20
Arvinas Inc, Key Competitors 21
Arvinas Inc, Key Employees 22

List of Figures
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Arvinas Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Viridian Group Investments Ltd:企業の戦略的SWOT分析
    Viridian Group Investments Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Feldan Bio Inc-製薬・医療分野:企業M&A・提携分析
    Summary Feldan Bio Inc (Feldan) is a biotechnology company. It discovers, develops, manufactures and markets research therapeutic and industrial protein products. The company offers cell therapy products, genome editing products and research products. Its genome editing product includes recombinant …
  • Genera Biosystems Ltd (GBI):医療機器:M&Aディール及び事業提携情報
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …
  • Active Biotech AB (ACTI)-製薬・医療分野:企業M&A・提携分析
    Summary Active Biotech AB (Active Biotech) is a biotechnology company that undertakes the development and commercialization of pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company has five projects in clinical development of which three have been licensed o …
  • ATI Physical Therapy:製薬・医療:M&Aディール及び事業提携情報
    Summary ATI Physical Therapy (ATI) is a healthcare service provider that offers therapy and healthcare services. The center offers therapy services such as hand therapy, women's health, workers' comp rehab, sports therapy, physical therapy, specialty therapies, home health and complimentary injury s …
  • Old Dominion Freight Line, Inc. (ODFL):企業の財務・戦略的SWOT分析
    Old Dominion Freight Line, Inc. (ODFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • The Blackstone Group LP:企業のM&A・事業提携・投資動向
    The Blackstone Group LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Blackstone Group LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • SRI International-医療機器分野:企業M&A・提携分析
    Summary SRI International (SRI) is a research institute which provides commercial research and development programs. It conducts research and development in the areas of biosciences, health and medical systems, chemistry and materials, communications and networks, computing, earth and space, economi …
  • SK Biopharmaceuticals Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a developer of drug candidates. The company develops and markets innovative drugs for the treatment of central nervous system. It offers plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL …
  • Mid-America Apartment Communities Inc (MAA):企業の財務・戦略的SWOT分析
    Summary Mid-America Apartment Communities, Inc. (MAA) is a real estate investment company that operates apartment homes. The company is engaged in property development, property management, redevelopment, acquisition, sales, marketing and financing. MAA provides web-based and technology driven suppo …
  • Nabors Industries Ltd.:企業の戦略・SWOT・財務分析
    Nabors Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nabors Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Venn Life Sciences Holdings Plc (VENN):企業の財務・戦略的SWOT分析
    Summary Venn Life Sciences Holdings Plc (Venn Life Sciences), formerly Armscote Investment Company Plc is a contract research organization that offers drug development, clinical trial management and resourcing solutions. The organization offers drug development services such as clinical pharmacology …
  • EBS Technologies GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary EBS Technologies GmbH (EBS) is a medical device company that develops stimulation system for visual field effect. The company offers Eyetronic Therapy, which has been developed for patients suffering from a progressive visual field loss due to glaucoma and other diseases of the optic nerve. …
  • Seek Limited
    Seek Limited - Strategy, SWOT and Corporate Finance Report Summary Seek Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Bayer AG (BAYN):企業の財務・戦略的SWOT分析
    Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Leadiant Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Leadiant Biosciences Inc (Leadiant Biosciences) a subsidiary of Sigma-Tau SpA is a pharmaceutical company that discovers and develops novel medicines. The company offers products such as Cystaran, Carnitor, Matulane, Adagen, Abelcet, DepoCyt, ProXeed Plus, VSL and Colief products. It offers …
  • Thermax Ltd (THERMAX):企業の財務・戦略的SWOT分析
    Thermax Ltd (THERMAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Silver Spring Networks, Inc. (SSNI)-エネルギー分野:企業M&A・提携分析
    Summary Silver Spring Networks, Inc. (Silver Spring) is a smart grid networking platform technology and solutions provider. The company’s products include metering devices, network infrastructure, utilityIQ applications, GridScape software and customerIQ web portal. Silver Spring provides wide range …
  • Boston-Power, Inc.-エネルギー分野:企業M&A・提携分析
    Summary Boston-Power, Inc. (Boston-Power) is a developer and manufacturer of lithium-ion battery and pack technologies. The company provides rechargeable lithium-ion cells under two brands, namely, Sonata and Swing. Its Sonata product range finds application in portable power and notebook computer m …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆